• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过在100摄氏度下额外进行干热处理提高经S/D处理的凝血因子VIII浓缩物的病毒安全性。

Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.

作者信息

Dichtelmüller H, Rudnick D, Breuer B, Kotitschke R, Kloft M, Darling A, Watson E, Flehmig B, Lawson S, Frösner G

机构信息

Biotest Pharma GmbH, Dreieich, Germany.

出版信息

Biologicals. 1996 Jun;24(2):125-30. doi: 10.1006/biol.1996.0016.

DOI:10.1006/biol.1996.0016
PMID:8889059
Abstract

In order to increase the virus safety of a solvent/detergent-treated Factor VIII concentrate in regard to non-lipid coated viruses and to respond to the continuous discussion about reports on hepatitis A transmission by Factor VIII preparations, we have investigated the effect of a terminal dry heat treatment (30 min 100 degrees C) on HAV and various other viruses. By this treatment Hepatitis A virus was inactivated below detectable level after a few minutes (> 5.3 log10). Other RNA viruses such as the Human Immunodeficiency Virus (> 6.6 log10), bovine viral diarrhoea virus (> 6.6 log10) and vesicular stomatitis virus (> 5.8 log10) were also inactivated below detectable level. Pseudo rabies virus and reovirus Type 3 are inactivated by 5.7 and > 6.0 log10, respectively. SV40 and bovine parvo virus showed significant resistance to dry heat treatment. We conclude that the involvement of two strong virus inactivation steps, acting by different mechanisms, improves the virus safety of Factor VIII concentrates without destroying the Factor VIII activity. Moreover, the terminal 100 degrees C heat treatment for 30 min represents an effective measure to inactivate non-lipid enveloped viruses, in particular hepatitis A, which is resistant to solvent/detergent treatment.

摘要

为了提高经溶剂/去污剂处理的凝血因子VIII浓缩物对非脂质包膜病毒的病毒安全性,并回应关于凝血因子VIII制剂传播甲型肝炎报告的持续讨论,我们研究了终端干热处理(100℃,30分钟)对甲型肝炎病毒及其他多种病毒的影响。通过这种处理,甲型肝炎病毒在几分钟内(>5.3 log10)就被灭活至检测不到的水平。其他RNA病毒,如人类免疫缺陷病毒(>6.6 log10)、牛病毒性腹泻病毒(>6.6 log10)和水疱性口炎病毒(>5.8 log10)也被灭活至检测不到的水平。伪狂犬病病毒和呼肠孤病毒3型分别被灭活5.7 log10和>6.0 log10。SV40和牛细小病毒对干热处理表现出显著抗性。我们得出结论,两个通过不同机制起作用的强效病毒灭活步骤的结合,在不破坏凝血因子VIII活性的情况下提高了凝血因子VIII浓缩物的病毒安全性。此外,100℃终端热处理30分钟是灭活非脂质包膜病毒,特别是对溶剂/去污剂处理有抗性的甲型肝炎病毒的有效措施。

相似文献

1
Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.通过在100摄氏度下额外进行干热处理提高经S/D处理的凝血因子VIII浓缩物的病毒安全性。
Biologicals. 1996 Jun;24(2):125-30. doi: 10.1006/biol.1996.0016.
2
Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.用于提高从人血浆制备的抗血友病因子VIII浓缩物病毒安全性的干热治疗工艺。
J Microbiol Biotechnol. 2008 May;18(5):997-1003.
3
"In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.关于一种双病毒灭活因子VIII浓缩物的“体外”及动物模型研究。
Thromb Haemost. 1995 Sep;74(3):868-73.
4
[Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].[对经过两种特定病毒灭活处理(FANDHI)的高纯度人凝血因子VIII浓缩物的病毒安全性评估]
Sangre (Barc). 1996 Apr;41(2):131-6.
5
Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.在凝血因子VIII浓缩物生产过程中通过巴氏消毒法灭活甲型肝炎病毒并消除小核糖核酸病毒。
Vox Sang. 1994;67 Suppl 1:62-6.
6
Viral safety of a new highly purified factor VIII (OCTATE).新型高纯度凝血因子VIII(OCTATE)的病毒安全性
J Med Virol. 1996 Apr;48(4):360-6. doi: 10.1002/(SICI)1096-9071(199604)48:4<360::AID-JMV10>3.0.CO;2-F.
7
Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.用氢氧化钠和加热处理对模型病毒及相关血源病毒的灭活动力学
Biologicals. 1998 Sep;26(3):237-44. doi: 10.1006/biol.1998.0146.
8
Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).新型高纯度双病毒灭活血管性血友病因子和凝血因子VIII浓缩剂(Wilate)的特性研究
Biologicals. 2006 Dec;34(4):281-8. doi: 10.1016/j.biologicals.2005.11.010. Epub 2006 Feb 23.
9
Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.巴氏消毒单克隆抗体凝血因子VIII浓缩剂:确立血浆源性浓缩剂纯度和病毒安全性的新标准。
Blood Coagul Fibrinolysis. 2000 Mar;11(2):203-15.
10
A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.一种经溶剂/去污剂处理、巴氏消毒且高度纯化的凝血因子 VIII 浓缩剂。
Arzneimittelforschung. 1994 Feb;44(2):188-91.

引用本文的文献

1
Human Immunodeficiency Virus (HIV).人类免疫缺陷病毒(HIV)
Transfus Med Hemother. 2016 May;43(3):203-22. doi: 10.1159/000445852. Epub 2016 May 9.
2
Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins.适配体作为一种灵敏的工具,可用于检测治疗性蛋白质中的细微修饰。
PLoS One. 2012;7(2):e31948. doi: 10.1371/journal.pone.0031948. Epub 2012 Feb 27.
3
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
血浆衍生物溶剂/去污剂处理的稳健性:来自血浆蛋白治疗协会成员公司的数据收集。
Transfusion. 2009 Sep;49(9):1931-43. doi: 10.1111/j.1537-2995.2009.02222.x. Epub 2009 May 20.